Brain tumor epidemiology: Consensus from the Brain Tumor Epidemiology Consortium, Cancer, vol.16, issue.2-3, pp.1953-68, 2008. ,
DOI : 10.1212/01.WNL.0000129533.26544.BF
URL : http://onlinelibrary.wiley.com/doi/10.1002/cncr.23741/pdf
Radiotherapy plus Concomitant and Adjuvant Temozolomide for Glioblastoma, New England Journal of Medicine, vol.352, issue.10, pp.987-96, 2005. ,
DOI : 10.1056/NEJMoa043330
Chemotherapy Delivery Issues in Central Nervous System Malignancy: A Reality Check, Journal of Clinical Oncology, vol.25, issue.16, pp.2295-305, 2007. ,
DOI : 10.1200/JCO.2006.09.9861
Clinical experience with alpha-particle emitting 211At: treatment of recurrent brain tumor patients with 211At-labeled chimeric antitenascin monoclonal antibody 81C6, J Nucl Med Off Publ Soc Nucl Med, vol.49, issue.1, pp.30-38, 2008. ,
I-Labeled Antitenascin Monoclonal Antibody 81C6 Administered Into Surgically Created Resection Cavities of Patients With Newly Diagnosed Malignant Gliomas, Journal of Clinical Oncology, vol.20, issue.5, pp.1389-97, 2002. ,
DOI : 10.1200/JCO.2002.20.5.1389
Recent Advances in the Treatment of Malignant Astrocytoma, Journal of Clinical Oncology, vol.24, issue.8, pp.1253-65, 2006. ,
DOI : 10.1200/JCO.2005.04.5302
Integrin ??v??3-Targeted Radioimmunotherapy of Glioblastoma Multiforme, Clinical Cancer Research, vol.14, issue.22, pp.7330-7339, 2008. ,
DOI : 10.1158/1078-0432.CCR-08-0797
URL : http://clincancerres.aacrjournals.org/content/clincanres/14/22/7330.full.pdf
Phase I single-dose study of intracavitary-administered Nimotuzumab labeled with 188-Re in adult recurrent high-grade glioma, Cancer Biology & Therapy, vol.7, issue.3, pp.333-342, 2008. ,
DOI : 10.4161/cbt.7.3.5414
Engineered liposomes for potential alpha-particle therapy of metastatic cancer, J Nucl Med Off Publ Soc Nucl Med, vol.45, issue.2, pp.253-60, 2004. ,
Rhenium-186 liposomes as convection-enhanced nanoparticle brachytherapy for treatment of glioblastoma, Neuro-Oncology, vol.14, issue.4, pp.416-441, 2012. ,
DOI : 10.1093/neuonc/nos060
Re-Labeled PEGylated Nanoliposome in Orthotopic Glioma Bearing Rat Model, Cancer Biotherapy & Radiopharmaceuticals, vol.26, issue.6, pp.717-742, 2011. ,
DOI : 10.1089/cbr.2011.1052
URL : https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3231795/pdf
A novel phase inversion-based process for the preparation of lipid nanocarriers, Pharmaceutical Research, vol.19, issue.6, pp.875-80, 2002. ,
DOI : 10.1023/A:1016121319668
188Re-loaded lipid nanocapsules as a promising radiopharmaceutical carrier for internal radiotherapy of malignant gliomas, European Journal of Nuclear Medicine and Molecular Imaging, vol.112, issue.10, pp.1838-1884, 2008. ,
DOI : 10.1016/j.ijrobp.2006.12.001
URL : https://hal.archives-ouvertes.fr/inserm-00343438
Tumor eradication in rat glioma and bypass of immunosuppressive barriers using internal radiation with 188Re-lipid nanocapsules, Biomaterials, vol.32, issue.28, pp.6781-90, 2011. ,
DOI : 10.1016/j.biomaterials.2011.05.067
URL : https://hal.archives-ouvertes.fr/inserm-00638699
Brain tumour stem cells, Nature Reviews Cancer, vol.6, issue.6, pp.425-461, 2006. ,
DOI : 10.1016/S0002-9440(10)61750-6
Identification of a cancer stem cell in human brain tumors, Cancer Res, vol.63, issue.18, pp.5821-5829, 2003. ,
Identification of human brain tumour initiating cells, Nature, vol.64, issue.7015, pp.396-401, 2004. ,
DOI : 10.1093/jnen/61.3.215
Isolation and Characterization of Tumorigenic, Stem-like Neural Precursors from Human Glioblastoma, Cancer Research, vol.64, issue.19, pp.7011-7032, 2004. ,
DOI : 10.1158/0008-5472.CAN-04-1364
Neural Stem Cells and the Origin of Gliomas, New England Journal of Medicine, vol.353, issue.8, pp.811-833, 2005. ,
DOI : 10.1056/NEJMra043666
Brain tumor stem cells: Molecular characteristics and their impact on therapy, Molecular Aspects of Medicine, vol.39, pp.82-101, 2014. ,
DOI : 10.1016/j.mam.2013.06.004
URL : https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3866208/pdf
Targeting Cancer Stem Cells through L1CAM Suppresses Glioma Growth, Cancer Research, vol.68, issue.15, pp.6043-6051, 2008. ,
DOI : 10.1158/0008-5472.CAN-08-1079
URL : http://cancerres.aacrjournals.org/content/canres/68/15/6043.full.pdf
Stem Cell???like Glioma Cells Promote Tumor Angiogenesis through Vascular Endothelial Growth Factor, Cancer Research, vol.66, issue.16, pp.7843-7851, 2006. ,
DOI : 10.1158/0008-5472.CAN-06-1010
URL : http://cancerres.aacrjournals.org/content/canres/66/16/7843.full.pdf
L1CAM regulates DNA damage checkpoint response of glioblastoma stem cells through NBS1, The EMBO Journal, vol.8, issue.5, pp.800-813, 2011. ,
DOI : 10.1038/nrd2137
URL : http://emboj.embopress.org/content/embojnl/30/5/800.full.pdf
Chemokine receptor trio: CXCR3, CXCR4 and CXCR7 crosstalk via CXCL11 and CXCL12, Cytokine & Growth Factor Reviews, vol.24, issue.1, pp.41-50, 2013. ,
DOI : 10.1016/j.cytogfr.2012.08.007
URL : https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4172454/pdf
The chemokine stromal cell derived factor-1 (CXCL12) promotes glioma invasiveness through MT2-matrix metalloproteinase, Carcinogenesis, vol.26, issue.12, pp.2069-77, 2005. ,
DOI : 10.1093/carcin/bgi183
URL : https://academic.oup.com/carcin/article-pdf/26/12/2069/17284584/bgi183.pdf
CXCR4 mediates the proliferation of glioblastoma progenitor cells, Cancer Letters, vol.274, issue.2, pp.305-317, 2009. ,
DOI : 10.1016/j.canlet.2008.09.034
Vasculogenesis: a crucial player in the resistance of solid tumours to radiotherapy, The British Journal of Radiology, vol.87, issue.1035, p.20130686, 1035. ,
DOI : 10.1259/bjr.20130686
Matrix Metalloproteinase-9 Is Required for Tumor Vasculogenesis but Not for Angiogenesis: Role of Bone Marrow-Derived Myelomonocytic Cells, Cancer Cell, vol.13, issue.3, pp.193-205, 2008. ,
DOI : 10.1016/j.ccr.2007.11.032
Targeting SDF-1/CXCR4 to inhibit tumour vasculature for treatment of glioblastomas, British Journal of Cancer, vol.277, issue.12, pp.1805-1814, 2011. ,
DOI : 10.1074/jbc.M206222200
Inhibition of vasculogenesis, but not angiogenesis, prevents the recurrence of glioblastoma after irradiation in mice, Journal of Clinical Investigation, vol.120, issue.3, pp.694-705, 2010. ,
DOI : 10.1172/JCI40283DS1
Stromal cell-derived factor 1alpha stimulates human glioblastoma cell growth through the activation of both extracellular signal-regulated kinases 1/2 and Akt, Cancer Res, vol.63, issue.8, pp.1969-74, 2003. ,
A kit formulation for the labelling of lipiodol with generator-produced188Re, Journal of Labelled Compounds and Radiopharmaceuticals, vol.9, issue.12, pp.857-67, 2004. ,
DOI : 10.1524/ract.1997.79.2.93
Development and characterization of immuno-nanocarriers targeting the cancer stem cell marker AC133, International Journal of Pharmaceutics, vol.423, issue.1, pp.93-101, 2012. ,
DOI : 10.1016/j.ijpharm.2011.06.001
Confocal spectral imaging analysis in studies of the spatial distribution of antitumour drugs within living cancer cells, Analytica Chimica Acta, vol.290, issue.1-2, pp.40-47, 1994. ,
DOI : 10.1016/0003-2670(94)80038-3
Differential Subcellular Distribution of Mitoxantrone in Relation to Chemosensitization in Two Human Breast Cancer Cell Lines, Drug Metabolism and Disposition, vol.35, issue.5, pp.822-830, 2007. ,
DOI : 10.1124/dmd.106.013474
Effect of particle size on the biodistribution of lipid nanocapsules: Comparison between nuclear and fluorescence imaging and counting, International Journal of Pharmaceutics, vol.453, issue.2, pp.594-600, 2013. ,
DOI : 10.1016/j.ijpharm.2013.05.057
Intérêt des nanosphères comme forme orale à libération modifiée pour améliorer la biodisponibilité et le profil pharmacodynamique de l'isradipine, Université Henri Poincaré -Nancy, vol.1, 1999. ,
Convection-enhanced delivery of nanocarriers for the treatment of brain tumors, Biomaterials, vol.30, issue.12, pp.2302-2320, 2009. ,
DOI : 10.1016/j.biomaterials.2009.01.003
Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm, Nature Immunology, vol.313, issue.10, pp.889-96, 2010. ,
DOI : 10.1016/j.ccr.2009.06.017
Biodistribution and internal dosimetry of the 188Re-labelled humanized monoclonal antibody anti-epidemal growth factor receptor, nimotuzumab, in the locoregional treatment of malignant gliomas, Nuclear Medicine Communications, vol.29, issue.1, pp.66-75, 2008. ,
DOI : 10.1097/MNM.0b013e3282f1bbce
Spontaneous and Ligand-induced Trafficking of CXC-Chemokine Receptor 4, Journal of Biological Chemistry, vol.72, issue.26, pp.15883-15889, 1998. ,
DOI : 10.1016/S0960-9822(06)00055-8
URL : http://www.jbc.org/content/273/26/15883.full.pdf
Functional expression of the CXC-chemokine receptor-4/fusin on mouse microglial cells and astrocytes, J Immunol Baltim Md, vol.159, issue.2, pp.905-916, 1950. ,
Hypoxia-inducible factor 1 and VEGF upregulate CXCR4 in glioblastoma: implications for angiogenesis and glioma cell invasion, Laboratory Investigation, vol.4, issue.12, pp.1221-1253, 2006. ,
DOI : 10.1038/nm1075
Expression of stem cell markers in human astrocytomas of different WHO grades, Journal of Neuro-Oncology, vol.47, issue.1, pp.31-45, 2008. ,
DOI : 10.1177/002215540205000203
CXCR4 expression mediates glioma cell invasiveness, Oncogene, vol.25, issue.19, pp.2801-2807, 2006. ,
DOI : 10.1074/jbc.M206222200
URL : http://www.nature.com/onc/journal/v25/n19/pdf/1209302a.pdf
Mechanisms of Glioma-Associated Neovascularization, The American Journal of Pathology, vol.181, issue.4, pp.1126-1167, 2012. ,
DOI : 10.1016/j.ajpath.2012.06.030
URL : https://doi.org/10.1016/j.ajpath.2012.06.030
A reappraisal of macrophage polarization in glioblastoma: Histopathological and immunohistochemical findings and review of the literature, Pathology - Research and Practice, vol.212, issue.6, pp.491-500, 2016. ,
DOI : 10.1016/j.prp.2016.02.020
CSF-1R inhibition alters macrophage polarization and blocks glioma progression, Nature Medicine, vol.102, issue.10, pp.1264-72, 2013. ,
DOI : 10.1073/pnas.0506580102
URL : https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3840724/pdf
Macrophage Polarization Contributes to Glioblastoma Eradication by Combination Immunovirotherapy and Immune Checkpoint Blockade, Cancer Cell, vol.32, issue.2, pp.253-267, 2017. ,
DOI : 10.1016/j.ccell.2017.07.006
Design of targeted lipid nanocapsules by conjugation of whole antibodies and antibody Fab??? fragments, Biomaterials, vol.28, issue.33, pp.4978-90, 2007. ,
DOI : 10.1016/j.biomaterials.2007.05.014
Convection-enhanced delivery of macromolecules in the brain., Proceedings of the National Academy of Sciences, vol.91, issue.6, pp.2076-80, 1994. ,
DOI : 10.1073/pnas.91.6.2076
Towards multidimensional radiotherapy (MD-CRT): biological imaging and biological conformality, International Journal of Radiation Oncology*Biology*Physics, vol.47, issue.3, pp.551-60, 2000. ,
DOI : 10.1016/S0360-3016(00)00467-3
Dose-painting by numbers: a feasible approach?, The Lancet Oncology, vol.6, issue.2, p.66, 2005. ,
DOI : 10.1016/S1470-2045(05)01718-3
« Dose-painting » : mythe ou réalité ? Cancer/Radiothérapie, pp.6-7554, 2010. ,
DOI : 10.1016/j.canrad.2010.06.005
Proton magnetic resonance spectroscopy imaging in the evaluation of patients undergoing gamma knife surgery for Grade IV glioma, Journal of Neurosurgery, vol.101, issue.3, pp.467-75, 2004. ,
DOI : 10.3171/jns.2004.101.3.0467
Reirradiation of recurrent high-grade gliomas using amino acid PET (SPECT)/CT/MRI image fusion to determine gross tumor volume for stereotactic fractionated radiotherapy, International Journal of Radiation Oncology*Biology*Physics, vol.63, issue.2, pp.511-520, 2005. ,
DOI : 10.1016/j.ijrobp.2005.01.056
Intratumoral heterogeneity in glioblastoma: don't forget the peritumoral brain zone, Neuro-Oncology, vol.17, issue.10, pp.1322-1354, 2015. ,
DOI : 10.1093/neuonc/nov119
Failure pattern following complete resection plus radiotherapy and temozolomide is at the resection margin in patients with glioblastoma, Journal of Neuro-Oncology, vol.88, issue.1, pp.19-23, 2013. ,
DOI : 10.1007/s11060-008-9576-7
Radiosensitivity enhancement of radioresistant glioblastoma by epidermal growth factor receptor antibody-conjugated iron-oxide nanoparticles, Journal of Neuro-Oncology, vol.91, issue.6, pp.13-22, 2015. ,
DOI : 10.1073/pnas.91.6.2076
URL : https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4498963/pdf
Targeted therapy of glioblastoma stem-like cells and tumor non-stem cells using cetuximab-conjugated iron-oxide nanoparticles, Oncotarget, vol.6, issue.11, pp.8788-806, 2015. ,
DOI : 10.18632/oncotarget.3554
Biodistribution of111In-labelled SCN-bz-DTPA-BC-2 MAb following loco-regional injection into glioblastomas, International Journal of Cancer, vol.49, issue.5, pp.810-816, 1997. ,
DOI : 10.1038/bjc.1993.25
URL : http://onlinelibrary.wiley.com/doi/10.1002/(SICI)1097-0215(19970529)71:5<810::AID-IJC19>3.0.CO;2-B/pdf
Nanomedicine to overcome radioresistance in glioblastoma stem-like cells and surviving clones, Trends in Pharmacological Sciences, vol.36, issue.4, pp.236-52, 2015. ,
DOI : 10.1016/j.tips.2015.02.002
Identification of Novel Small Molecule Inhibitors of Hypoxia-Inducible Factor-1 That Differentially Block Hypoxia-Inducible Factor-1 Activity and Hypoxia-Inducible Factor-1?? Induction in Response to Hypoxic Stress and Growth Factors, Cancer Research, vol.65, issue.11, pp.4918-4946, 2005. ,
DOI : 10.1158/0008-5472.CAN-04-4453
CXCR7 (RDC1) promotes breast and lung tumor growth in vivo and is expressed on tumor-associated vasculature, Proceedings of the National Academy of Sciences, vol.100, issue.20, pp.15735-15775, 2007. ,
DOI : 10.1073/pnas.1933744100
URL : http://www.pnas.org/content/104/40/15735.full.pdf
CXCL12 modulation of CXCR4 and CXCR7 activity in human glioblastoma stem-like cells and regulation of the tumor microenvironment, Front Cell Neurosci, vol.8, p.144, 2014. ,
Inhibition of CXCR7 extends survival following irradiation of brain tumours in mice and rats, British Journal of Cancer, vol.110, issue.5, pp.1179-88, 2014. ,
DOI : 10.1152/physiolgenomics.00147.2007
Inhibiting Vasculogenesis After Radiation: A New Paradigm to Improve Local Control by Radiotherapy, Semin Radiat Oncol, vol.23, issue.4, pp.281-288, 2013. ,
First-in-Human Experience of CXCR4-Directed Endoradiotherapy with 177Lu- and 90Y-Labeled Pentixather in Advanced-Stage Multiple Myeloma with Extensive Intra- and Extramedullary Disease, Journal of Nuclear Medicine, vol.57, issue.2, pp.248-51, 2016. ,
DOI : 10.2967/jnumed.115.167361
Analysis of immunoreactivity of free 12G5 antibody and 12G5-LNCs as a function of time after storage at 4°C determined by flow cytometry on U87MG transfected cells. The free 12G5 antibody and 12G5-LNCs labeled U87MG CXCR4+ cells. 12G5-LNCs labeling remains stable for 3 days. Statistical analysis was performed with the log-rank test ,
Western blot analysis of the phosphorylation of Akt in U87MG CXCR4+ cells 16 hours after stimulation by SDF-1 at 25nM depending from the presence of LNC formulations, 12G5-LNC, IgG2a-LNCs and LNCs) or not (PBS) ,